Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
Threads is finally launching on desktop
MrBeast announces 'Extreme Olympics' video featuring a budget of over $4M, fans call YouTuber's content 'unmatched'
'He obviously did it for money': Twitch star Pokimane reacts to Mizkif joining Rumble
When Does Apex Legends Season 18 End?
New iPhone, new charger: Apple bends to EU rules
Apex Legends Pick Rates October 2023: Most Popular Characters
Logitech MX Anywhere 3S Review
How tall is Adin Ross? Internet once mocked Kick streamer for being 'insecure' about his height